Background: In 2020, melanoma exhibited the 5th highest incidence rate of all cancers in the US. While metastatic melanoma constitutes only 4% of new melanoma cases, the 5-year survival rate of metastatic melanoma is 27% [1]. Immune Checkpoint Inhibitors (ICIs) were the first drugs to significantly improve the 5-year survival of late-stage melanoma patients; these [...]

Case Presentation: A 79-year-old Caucasian male presented to the hospital with complaints of worsening generalized weakness, difficulty swallowing, and shortness of breath for about 3 weeks. His past medical history was significant for metastatic melanoma (metastasis to brain, lung). He received his first session of immunotherapy with Ipilimumab and Nivolumab one month before his presentation [...]

Case Presentation: A 58-year-old man with type 2 diabetes, hypertension, peripheral arterial disease, and right fifth toe amputation for osteomyelitis presented to the emergency room with pain at the site of a non-healing right foot ulcer. When the pain started two years prior, the patient was diagnosed with a diabetic foot infection (DFI) from poorly [...]

Case Presentation: This is a case of a 72-year-old male with Stage III metastatic melanoma. The patient was started on combination immunotherapy with ipilimumab and nivolumab three months prior. He completed three cycles of treatment. He presented to the emergency department with complaints of fatigue and lethargy. Initial assessment of vitals showed hypotension, BP 95/61 [...]